Development of aceptic osteonecrosis during the treatment of acute lymphoblastic leukemia: review of the literature and original data


Cite item

Full Text

Abstract

We report a case of aceptic osteonecrosis (AON) of the left hymerus epiphysis in programmed treatment of a male patient with lymphoblastic lymphoma to illustrate clinical, laboratory, epidemiological, pathogenetic, diagnostic and therapeutic aspects of AON in programmed therapy of acute lymphoblastic leukemia (ALL). We believe that AON is a rather frequent but often missed for early diagnosis complication of ALL treatment. Even a weak pain in bones and joints under mechanical load in patients on long-term treatment with glucocorticosteroids is an alarming symptom which may indicate a risk of an osteodestructive process and relevant diagnostic and therapeutic measures may be needed.

About the authors

Ol'ga Yur'evna Baranova

Email: baranova-crc@mail.ru

Anton Dmitrievich Shirin

Natal'ya Aleksandrovna Falaleeva

Evgeniy Aleksandrovich Osmanov

O Yu Baranova

N.N. Blokhin Russian Cancer Research Center, Moscow

N.N. Blokhin Russian Cancer Research Center, Moscow

A D Shirin

N.N. Blokhin Russian Cancer Research Center, Moscow

N.N. Blokhin Russian Cancer Research Center, Moscow

N A Falaleeva

N.N. Blokhin Russian Cancer Research Center, Moscow

N.N. Blokhin Russian Cancer Research Center, Moscow

D Sh Osmanov

N.N. Blokhin Russian Cancer Research Center, Moscow

N.N. Blokhin Russian Cancer Research Center, Moscow

References

  1. Pui C. H., Evans W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 2006; 354 (2): 166-178.
  2. Pui C. H., Robison L. L., Look A. T. Acute lymphoblastic leukaemia. Lancet. 2008; 371 (9617): 1030-1043.
  3. Fielding A. The treatment of adults with acute lymphoblastic leukemia. Hematology. 2008: 381-389.
  4. Marks D . I. Treating the "older" adult with acute lymphoblastic leukemia. Hematology. 2010: 13-20.
  5. Gaynon P. S., Lustig R. H. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: Molecular, cellular, and clinical considerations. J. Pediatr. Hematol. Oncol. 1995; 17: 1-12.
  6. Mattano L. The skeletal remains: Porosis and necrosis of bone in the marrow transplantation setting. Pediatr. Transplant. 2003; 7 (Suppl. 3): 71-75.
  7. Mattano L. A. Jr., Sather H. N., Trigg M. E. et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J. Clin. Oncol. 2000; 18: 3262-3272.
  8. Arico M., Boccalatte M. F., Silvestri D. et al. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematol. 2003; 88: 747- 753.
  9. Vegna M. L. Avascular necrosis of the femoral head in acute leukemia patients treated with combination therapy including steroids. Eur. J. Haematol. 1989; 42: 209-211.
  10. Halleux C. M., Declerck P. J., Tran S. L. et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J. Clin. Endocrinol. 1999; 84: 4097-4105.
  11. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
  12. Kathiresan S., Gabriel S. B., Yang Q. et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005; 112: 1728-1735.
  13. Dawson S. J., Wiman В., Hamsten A. et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 1993;268: 10 739-10 745.
  14. Festa A., D'Agostino R. Jr., Rich S. S. et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107: 2422-2427.
  15. French D., Hamilton L. H., Mattano L. A. Jr. et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111(9): 4496-4499.
  16. Motomura G., Yamamoto Т., Miyanishi K. et al. Bone marrow fat-cell enlargement in early steroid-induced osteonecrosis: A histomorphometric study of autopsy cases. Pathol. Res. Pract. 2005; 200: 807-811.
  17. Wang G. J., Sweet D. E., Reger S. I. et al. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J. Bone J. Surg. Am. 1977; 59: 729-735.
  18. Miyanishi K., Yamamoto Т., Irisa Т. et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002; 30: 185-190.
  19. Sala A., Mattano L. A. Jr., Barr R. D. Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. Eur. J. Cancer 2007; 43(4): 683-689.
  20. Szepesi K., Posan E., Harsfalvi J. et al. The most severe forms of Perthes'disease associated with the homozygousactor V Leiden mutation. J. Bone J. Surg. Br. 2004; 86: 426-429.
  21. Glueck C. J., Fontaine R. N., Gruppo R. et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin. Orthop. Relat. Res. 1999; 35: 133-146.
  22. Yang L., Panetta J. C., Cai X. et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J. Clin. Oncol. 2008; 26: 1932-1939.
  23. Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J. Thromb. Haemost. 2005; 3: 292- 299.
  24. Kishi S., Griener J. C., Cheng C. et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 2003; 21: 3084-3091.
  25. Nysom K., Holm K., Hertz H. et al. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J. Clin. Oncol. 2001; 19(11): 2970-2971.
  26. Strauss A. J., Su J. T., Dalton V. M. et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J. Clin. Oncol. 2001; 19: 3066-3072.
  27. Burger В., Beier R., Zimmermann M. et al. Osteonecrosis: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL): Experiences from trial ALL-BFM 95. Pediatr. Blood Cancer 2005; 44: 220-225.
  28. Ojala A. E., Lanning P. P., Paakko E. et al. Osteonecrosis in children treated for acute lymphoblastic leukemia: A magnetic resonance imaging study after treatment. Med. Pediatr. Oncol. 1997; 29: 260-265.
  29. Ojala A. E., Paakko E., Lanning F. P. et al. Osteonecrosis during the treatment of childhood acute lymphoblastic leukemia: A prospective MRI study. Med. Pediatr. Oncol. 1999; 32: 11- 17.
  30. Ribeiro R. C., Fletcher B. D., Kennedy W. et al. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 2001; 15: 891-897.
  31. Kawedia J. D., Kaste S. C., Pei D. et al. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011, 117: 2340-2347.
  32. Relling M. V., Yang W., Das S. et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol. 2004; 22: 3930-3936.
  33. Patel В., Richards S. M., Rowe J. M. et al. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukemia: a UKALL XII analysis. Leukemia 2008; 22(2): 308-312.
  34. Lee W. Y., Kang M. I., Baek K. H. et al. The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-yearprospective study. J. Korean Med. Sci. 2002; 17: 749-754.
  35. Haajanen J., Saarinen O., Laasonen L. et al. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients. Transplant. Proc. 1984; 16(5): 1316-1319.
  36. Ruderman R. J., Poehling G. G., Gray R. et al. Orthopedic complications of renal transplantation in children. Transplant. Proc. 1979; 11(1): 104-106.
  37. Niinimki R. A., Harila-Saari A. H., Jartti A. E. et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J. Clin. Oncol. 2007; 25 (12): 1498-1504.
  38. Strauss A. J., Su J. T., Kimball Dalton V. M. et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J. Clin. Oncol. 2001; 19: 3066-3072.
  39. Hurwitz C. A., Silverman L. B., Schorin M. A. et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88: 1964-1969.
  40. Wasilewski-Masker К., Kaste S. С., Hudson M. M. et al. Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics 2008; 121: e705-e713.
  41. Karimova E. J., Rai S. N., Howard S. C. et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J. Clin. Oncol. 2007; 25: 1525-1531.
  42. Marchese V. G., Connolly В. Н., Able C. et al. Relationships among severity of osteonecrosis, pain, range оf motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Physic. Ther. 2008; 88: 341-350.
  43. Угнивенко В. И. Комплексное лечение больных с нарушениями функции нижних конечностей в амбулаторных условиях: Пособие для врачей. М: ЦИТО; 1999. 28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies